Upgrade to SI Premium - Free Trial

Pacira Pharma (PCRX) Tops Q2 EPS by 6c, Revenues Beat; Provides FY19 Sales Outlook

August 8, 2019 8:04 AM
Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Earnings Management Comments

Next Articles